Compare AbbVie Inc (ABBV) vs FirstEnergy Corp. (FE) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

FirstEnergy (FE) trades at $48.39, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $52.25. The company reported revenue of $15.09 billion in 2025, with net income of $1.02 billion, and recent earnings have mostly beaten expectations. Positive news highlights growth from data center demand and a $36 billion investment plan for grid upgrades.

The outlook is supported by earnings visibility and strategic investments, but risks include regulatory uncertainty and high debt levels. With no sell ratings from analysts and a dividend payout scheduled, FE presents a steady utility investment with moderate upside potential balanced by sector-specific headwinds.